{"id":390012,"date":"2021-06-07T00:00:00","date_gmt":"2021-06-07T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptocg0014-2021-biopharma-special-topics-comorbidities-in-major-depressive-disorder-us\/"},"modified":"2026-03-31T10:43:11","modified_gmt":"2026-03-31T10:43:11","slug":"sptocg0014-2021-biopharma-special-topics-comorbidities-in-major-depressive-disorder-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptocg0014-2021-biopharma-special-topics-comorbidities-in-major-depressive-disorder-us\/","title":{"rendered":"Special Topics | Comorbidities in Major Depressive Disorder | US"},"content":{"rendered":"<p>Disorders\u00a0such as anxiety, substance use disorder, and insomnia\u00a0frequently coexist with major depressive disorder (MDD) and\u00a0present treatment challenges to\u00a0psychiatrists and primary care physicians (PCPs). Although multiple pharmacotherapies are available to manage MDD, none are FDA-approved specifically to treat MDD patients with a comorbid disorder. Additionally, a weak late-phase clinical pipeline for MDD and any comorbid disorder represents potential opportunities for drug development and areas of clinical differentiation from existing agents.<\/p>\n<p><strong>QUESTIONS ANSWERED <\/strong><\/p>\n<ul>\n<li>Which comorbid disorders are most common in MDD patients? How do physicians treat MDD patients with comorbid anxiety, substance use disorder, or insomnia?<\/li>\n<li>What factors most influence physicians\u2019 choice of current therapies for\u00a0MDD patients with comorbid anxiety, substance use disorder, or insomnia?<\/li>\n<li>How do branded drugs\u00a0such as Otsuka \/ Lundbeck\u2019s Rexulti, Janssen\u2019s Spravato, and Takeda \/ Lundbeck\u2019s Trintellix\u00a0fit into physicians\u2019 treatment of\u00a0patients with MDD and a comorbid anxiety disorder?<\/li>\n<li>How do physicians anticipate prescribing therapies in development for MDD comorbid with insomnia (i.e., Janssen\u2019s seltorexant [JNJ-42847922]\u00a0and Sage Therapeutics\u2019 zuranolone\u00a0[SAGE-217])\u00a0when they become available?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION <\/strong><\/p>\n<p>Clarivate\u2019s <em>Special Topics<\/em> reports assess key trends in dynamic disease areas. This report on comorbidities\u00a0of\u00a0MDD will help drug marketers and developers gain needed insight\u00a0on physician-reported treatment dynamics, prescribing behavior, key challenges managing MDD patients with comorbidities\u00a0such as anxiety disorder, substance use disorder, and insomnia, most important attributes for emerging therapies for\u00a0these comorbid disorders, and physician perceptions of select emerging therapies for\u00a0MDD and comorbid insomnia.<\/p>\n<p><strong>CONTENT HIGHLIGHTS<\/strong><\/p>\n<p><strong>Geographies:<\/strong> United States.<\/p>\n<p><strong>Primary research:<\/strong> Survey of 100 U.S. psychiatrists and PCPs. Interviews with three U.S. psychiatrists.<\/p>\n<p><strong>Key drugs covered:<\/strong> SSRIs, SNRIs, mixed serotonin modulators, atypical antipsychotics, NMDA receptor antagonists, mood stabilizers, opioid receptor antagonist, opioid receptor agonists, benzodiazepines, nonbenzodiazepine sedative-hypnotics, melatonin receptor agonists, dual orexin receptor antagonist, seltorexant, and zuranolone.<\/p>\n<p><strong>Key insights provided:<\/strong><\/p>\n<ul>\n<li>Patient characteristics.<\/li>\n<li>Physician treatment practices and physician insight\u00a0on medical practice.<\/li>\n<li>Most important attributes for emerging therapies.<\/li>\n<li>Anticipated use of emerging therapies.<\/li>\n<li>Physician perception of unmet need.<\/li>\n<li>Impact of COVID-19 on physician management.<\/li>\n<li>Physician recommendation of digital therapeutics.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390012","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-major-depressive-disorder","biopharma-therapy-areas-unipolar-depression","biopharma-product-special-topics-other","biopharma-geography-us","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390012","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390012\/revisions"}],"predecessor-version":[{"id":393137,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390012\/revisions\/393137"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390012"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}